{"organizations": [], "uuid": "ae1e5b7fc62594b8b4f4076d47a45356232eb3c2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180202.html", "section_title": "Archive News &amp; Video for Friday, 02 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL8N1PS1MM", "country": "US", "domain_rank": 408, "title": "BRIEF-Crossject Announces FDA Attributed To Zeneo Midazolam The Oprhan Drug Status", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.143, "site_type": "news", "published": "2018-02-02T15:57:00.000+02:00", "replies_count": 0, "uuid": "ae1e5b7fc62594b8b4f4076d47a45356232eb3c2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL8N1PS1MM", "ord_in_thread": 0, "title": "BRIEF-Crossject Announces FDA Attributed To Zeneo Midazolam The Oprhan Drug Status", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "usa", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 2 (Reuters) - Crossject SA:\n* ANNOUNCED ON THURSDAY THAT FDA ATTRIBUTED TO ZENEO MIDAZOLAM THE OPRHAN DRUG STATUS\n* CROSSJECT CONFIRMS THE OBJECTIVE OF RA SUBMISSION FOR ZENEO MIDAZOLAM IN 2019, IN THE USA AND IN EUROPE\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T15:57:00.000+02:00", "crawled": "2018-02-03T21:18:52.000+02:00", "highlightTitle": ""}